Progress on diagnosis and treatment of drug-resistant tuberculosis in line with World Health Organization recommendations in six priority countries in the Western Pacific Region.

IF 1 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Kyung Hyun Oh, Maria Imelda Quelapio, Fukushi Morishita, Kalpeshsinh Rahevar, Manami Yanagawa, Tauhid Islam
{"title":"Progress on diagnosis and treatment of drug-resistant tuberculosis in line with World Health Organization recommendations in six priority countries in the Western Pacific Region.","authors":"Kyung Hyun Oh,&nbsp;Maria Imelda Quelapio,&nbsp;Fukushi Morishita,&nbsp;Kalpeshsinh Rahevar,&nbsp;Manami Yanagawa,&nbsp;Tauhid Islam","doi":"10.5365/wpsar.2022.13.4.972","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diagnosis and treatment of drug-resistant tuberculosis (DR-TB) have radically changed in accordance with recommendations from the World Health Organization (WHO) in the past decade, allowing rapid and simple diagnosis and shorter treatment duration with new and repurposed drugs.</p><p><strong>Methods: </strong>A descriptive analysis of the status and progress of DR-TB diagnosis and treatment in six priority countries in the Western Pacific Region was conducted using information from interviews with countries and the WHO TB database.</p><p><strong>Results: </strong>Over the past decade, the use of Xpert MTB/RIF has increased in the six priority countries, in parallel with implementation of national policies and algorithms to use Xpert MTB/RIF as an initial diagnostic test for TB and detection of rifampicin resistance. This has resulted in increases in the number of people diagnosed with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB). Shorter treatment regimens with new and repurposed drugs have also been adopted for MDR/RR-TB cases, alongside a decentralized model of care, leading to improved treatment outcomes.</p><p><strong>Discussion: </strong>The Western Pacific Region has achieved considerable progress in the diagnosis and treatment of DR-TB, in line with the evolving WHO recommendations in the past decade. The continued commitment of Member States is needed to address remaining challenges, such as the impact of the coronavirus disease pandemic, suboptimal management and health system issues.</p>","PeriodicalId":31512,"journal":{"name":"Western Pacific Surveillance and Response","volume":"13 4","pages":"1-12"},"PeriodicalIF":1.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912284/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Western Pacific Surveillance and Response","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5365/wpsar.2022.13.4.972","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Diagnosis and treatment of drug-resistant tuberculosis (DR-TB) have radically changed in accordance with recommendations from the World Health Organization (WHO) in the past decade, allowing rapid and simple diagnosis and shorter treatment duration with new and repurposed drugs.

Methods: A descriptive analysis of the status and progress of DR-TB diagnosis and treatment in six priority countries in the Western Pacific Region was conducted using information from interviews with countries and the WHO TB database.

Results: Over the past decade, the use of Xpert MTB/RIF has increased in the six priority countries, in parallel with implementation of national policies and algorithms to use Xpert MTB/RIF as an initial diagnostic test for TB and detection of rifampicin resistance. This has resulted in increases in the number of people diagnosed with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB). Shorter treatment regimens with new and repurposed drugs have also been adopted for MDR/RR-TB cases, alongside a decentralized model of care, leading to improved treatment outcomes.

Discussion: The Western Pacific Region has achieved considerable progress in the diagnosis and treatment of DR-TB, in line with the evolving WHO recommendations in the past decade. The continued commitment of Member States is needed to address remaining challenges, such as the impact of the coronavirus disease pandemic, suboptimal management and health system issues.

Abstract Image

Abstract Image

Abstract Image

按照世界卫生组织的建议在西太平洋区域六个重点国家诊断和治疗耐药结核病方面取得的进展。
背景:在过去十年中,根据世界卫生组织(世卫组织)的建议,耐药结核病(DR-TB)的诊断和治疗发生了根本性的变化,可以快速和简单地诊断并缩短使用新药和改用药物的治疗时间。方法:对西太平洋地区6个重点国家耐药结核病的诊断和治疗现状和进展进行描述性分析,使用来自各国访谈和世卫组织结核病数据库的信息。结果:在过去十年中,Xpert MTB/RIF在六个重点国家的使用有所增加,同时实施了国家政策和算法,将Xpert MTB/RIF作为结核病的初始诊断检测和利福平耐药性检测。这导致被诊断为耐多药或耐利福平结核病(MDR/RR-TB)的人数增加。对于耐多药/耐药结核病病例,还采用了使用新药和改换用途药物的较短治疗方案,同时采用了分散的护理模式,从而改善了治疗结果。讨论:根据世卫组织在过去十年不断演变的建议,西太平洋区域在耐药结核病的诊断和治疗方面取得了相当大的进展。需要会员国继续作出承诺,以应对仍然存在的挑战,例如冠状病毒病大流行的影响、不理想的管理和卫生系统问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Western Pacific Surveillance and Response
Western Pacific Surveillance and Response PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
1.70
自引率
0.00%
发文量
23
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信